A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Alisertib (Primary) ; Bortezomib (Primary) ; Rituximab
- Indications B-cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
Most Recent Events
- 21 Mar 2025 Planned End Date changed from 5 Mar 2025 to 19 Mar 2026.
- 04 Dec 2018 Results assessing safety and efficacy of Alisertib in combination with bortezomib and rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 16 Feb 2018 Planned primary completion date changed from 30 Dec 2017 to 31 Mar 2019.